ASCO19: Round-up for day one, two and three…

With the American Society of Clinical Oncology (ASCO) annual meeting in full swing, staying on top of the key presentations is hard enough. So what about those that may have slipped under your radar over the first three days? FirstWord has rounded them up below:

  • Aduro's ADU-S100 in combination with Novartis' spartalizumab in patients with advanced/metastatic solid tumours or lymphomas
  • Nektar's NKTR-214, Opdivo combination in patients with metastatic Stage IV melanoma
  • Moderna's personalised cancer vaccine mRNA-4157 in solid tumours
  • Iovance's LN-145 in recurrent, metastatic or persistent cervical cancer
  • Turning Point Therapeutics' repotrectinib in ROS1-positive non-small-cell lung cancer

 

Aduro's ADU-S100 in combination with Novartis' spartalizumab in patients with advanced/metastatic solid tumours or lymphomas

Updated results from an ongoing Phase Ib study presented Sunday showed that the combination of Aduro Biotech's STING pathway activator ADU-S100 and Novartis' anti-PD1 monoclonal antibody spartalizumab in patients with advanced/metastatic solid tumours or lymphoma led to responses in some subjects with PD-1-naive triple-negative breast cancer (TNBC) and PD-1-relapsed or refractory melanoma. Specifically, five patients enrolled in the weekly group achieved confirmed responses, including one complete response (CR) and two partial responses (PRs) in anti-PD-1-naïve subjects with TNBC, as well as two PRs in previously immunotherapy-treated melanoma.

Data were presented based on findings from 83 enrolled patients, with 53 subjects in the weekly group and 30 in the monthly group. Results showed that 12 patients in the weekly group achieved stable disease (SD), including five who maintained SD for five months or more, while in the monthly group, six patients achieved SD, including five who maintained SD for five months or more.

Nektar's NKTR-214, Opdivo combination in patients with metastatic Stage IV melanoma

Nektar Therapeutics on Saturday presented updated results from the Phase I/II PIVOT-02 study investigating the CD122-preferential IL-2 pathway agonist NKTR-214 in combination with Bristol-Myers Squibb's Opdivo (nivolumab) in previously untreated patients with metastatic Stage IV melanoma, supporting its notion of deepening responses over time. Data released at last year's ASCO meeting showed that the CR rate was 11 percent, rising to 24 percent when results were updated a few months later.

In the latest update, results demonstrated that the CR rate was 34 percent in 38 efficacy-evaluable patients, with 42 percent achieving a maximum reduction of 100 percent in target lesions. Nektar added that of the 20 patients who responded to treatment with NKTR-214 plus Opdivo, 80 percent have ongoing responses, while the median duration of response and progression-free survival have not yet been reached. 

Moderna's personalised cancer vaccine mRNA-4157 in solid tumours

Moderna on Saturday released interim data from an ongoing Phase I study of its mRNA personalised cancer vaccine mRNA-4157, given alone or in combination with Merck & Co.'s Keytruda (pembrolizumab), in patients with solid tumours. Results showed that six out of 20 patients who received at least one dose of mRNA-4157 in combination with Keytruda responded to treatment, with one CR and five PRs. The company noted that the CR followed treatment with Keytruda, prior to dosing of mRNA-4157.

According to Moderna, immunogenicity response data was available from one patient, with neoantigen-specific CD8 T-cell responses detected to 10 out of 18 class I neoantigens after the fourth dose of mRNA-4157, compared to zero at baseline. "This study demonstrates the ability of Moderna's mRNA personalized cancer vaccine to elicit T-cells that are specific to the cancer mutations," remarked chief medical officer Tal Zaks.

Iovance's LN-145 in recurrent, metastatic or persistent cervical cancer

Having been picked as a highlight when ASCO abstracts were published earlier in May, Iovance Biotherapeutics was first out of the blocks on day one of the meeting with more data for its experimental immunotherapy LN-145. The company, which is developing drugs based on its tumour-infiltrating lymphocyte (TIL) technology, had earlier flagged an objective response rate (ORR) of 44 percent in 12 patients with recurrent, metastatic or persistent cervical cancer in the Phase II innovaTIL-04 study, consisting of one CR, nine PRs and two unconfirmed PRs, with a disease control rate of 89 percent.

Results detailed on Friday reaffirmed the ORR, but this time in 27 patients, comprising three CRs and nine PRs, with the disease control rate dropping to 85 percent. Having previously said that at 3.5-month median follow-up, 11 out of 12 patients maintained a response, Iovance noted at ASCO that at 7.4-month median follow-up, 10 patients maintained a response.

Turning Point Therapeutics' repotrectinib in ROS1-positive non-small-cell lung cancer

Turning Point Therapeutics updated results from the Phase I/II TRIDENT-1 study investigating the experimental drug repotrectinib in ROS1-positive non-small-cell lung cancer (NSCLC) patients. The company reported initial data last year, with updated results at ASCO showing an overall response rate (ORR) of 82 percent in 11 tyrosine kinase inhibitor (TKI)-naïve patients. Meanwhile, the ORR was 32 percent in 22 patients previously treated with a TKI, which rose to 55 percent when only including those subjects who received repotrectinib at the likely recommended Phase II dose or above.

Further results showed that in five patients with the G2032R solvent front mutation who had previously been treated with Merck KGaA and Pfizer's Xalkori (crizotinib), the ORR was 40 percent. However, Turning Point said that none of four patients who had been treated with two or more prior TKIs responded to repotrectinib. Following the update, shares in the company fell nearly as much as 15 percent on Friday.

To read more Top Story articles, click here.